These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 36225299)

  • 1. Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies.
    Kawana M; Spudich JA; Ruppel KM
    Front Physiol; 2022; 13():975076. PubMed ID: 36225299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline and Longitudinal Imaging of Hypertrophic Cardiomyopathy in the Era of Emerging Therapeutics.
    Altibi A; Alani A; Zhao Y; Masri A
    Curr Cardiol Rep; 2023 Jun; 25(6):583-595. PubMed ID: 37103749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy.
    Toepfer CN; Garfinkel AC; Venturini G; Wakimoto H; Repetti G; Alamo L; Sharma A; Agarwal R; Ewoldt JK; Cloonan P; Letendre J; Lun M; Olivotto I; Colan S; Ashley E; Jacoby D; Michels M; Redwood CS; Watkins HC; Day SM; Staples JF; Padrón R; Chopra A; Ho CY; Chen CS; Pereira AC; Seidman JG; Seidman CE
    Circulation; 2020 Mar; 141(10):828-842. PubMed ID: 31983222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertrophic Cardiomyopathy: Diverse Pathophysiology Revealed by Genetic Research, Toward Future Therapy.
    Hayashi T
    Keio J Med; 2020 Dec; 69(4):77-87. PubMed ID: 32224552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Genetic Basis of Hypertrophic Cardiomyopathy.
    Marian AJ
    Circ Res; 2021 May; 128(10):1533-1553. PubMed ID: 33983830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten.
    Mathai S; Williams L
    Ther Adv Chronic Dis; 2022; 13():20406223221136074. PubMed ID: 36407022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathy.
    Kawana M; Sarkar SS; Sutton S; Ruppel KM; Spudich JA
    Sci Adv; 2017 Feb; 3(2):e1601959. PubMed ID: 28246639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline.
    Tamargo J; Tamargo M; Caballero R
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1027-1052. PubMed ID: 36062808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca
    Sparrow AJ; Watkins H; Daniels MJ; Redwood C; Robinson P
    Am J Physiol Heart Circ Physiol; 2020 Mar; 318(3):H715-H722. PubMed ID: 32083971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects for remodeling the hypertrophic heart with myosin modulators.
    Sewanan LR; Shimada YJ
    Front Cardiovasc Med; 2022; 9():1051564. PubMed ID: 36330009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the sarcomere in inherited cardiomyopathies.
    Lehman SJ; Crocini C; Leinwand LA
    Nat Rev Cardiol; 2022 Jun; 19(6):353-363. PubMed ID: 35304599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy.
    Tower-Rader A; Ramchand J; Nissen SE; Desai MY
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1171-1178. PubMed ID: 32897741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of force-pCa relation in
    Yuan CC; Kazmierczak K; Liang J; Ma W; Irving TC; Szczesna-Cordary D
    Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35177471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.
    Dong T; Nissen S; Ospina S; Desai MY
    Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy.
    Zampieri M; Argirò A; Marchi A; Berteotti M; Targetti M; Fornaro A; Tomberli A; Stefàno P; Marchionni N; Olivotto I
    Curr Cardiol Rep; 2021 Jun; 23(7):79. PubMed ID: 34081217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mavacamten decreases maximal force and Ca
    Awinda PO; Watanabe M; Bishaw Y; Huckabee AM; Agonias KB; Kazmierczak K; Szczesna-Cordary D; Tanner BCW
    Am J Physiol Heart Circ Physiol; 2021 Feb; 320(2):H881-H890. PubMed ID: 33337957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.
    Marian AJ; Braunwald E
    Circ Res; 2017 Sep; 121(7):749-770. PubMed ID: 28912181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The genetic basis of hypertrophic cardiomyopathy in cats and humans.
    Kittleson MD; Meurs KM; Harris SP
    J Vet Cardiol; 2015 Dec; 17 Suppl 1(Suppl 1):S53-73. PubMed ID: 26776594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
    Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small Molecules acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases.
    Alsulami K; Marston S
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33339418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.